Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | MGAM | O43451 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | SI | P14410 | 2/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389644 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2TSHRMGAMGAASI | |
| SCHEMBL3396195 | 0.85 | MGAM (0.43) | SMN1; SMN2TSHRMGAMGAASI | |
| SCHEMBL3397834 | 0.85 | MGAM (0.43) | SMN1; SMN2TSHRMGAMGAASI | |
| SCHEMBL3397234 | 0.85 | GAA (0.48) | SMN1; SMN2TSHRMGAMGAASI | |
| SCHEMBL3394662 | 0.85 | GAA (0.48) | SMN1; SMN2TSHRMGAMGAASI | |
| SCHEMBL5081302 | 0.83 | TSHR (0.50) | SMN1; SMN2TSHRMGAMGAASI | |
| SCHEMBL5077875 | 0.83 | TSHR (0.50) | SMN1; SMN2TSHRMGAMGAASI | |
| SCHEMBL16626900 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD17B10MAPTCA1CA2 | |
| SCHEMBL3396358 | 0.82 | TSHR (0.33) | SMN1; SMN2TSHRMGAMGAASI | |
| SCHEMBL3396035 | 0.82 | TSHR (0.33) | SMN1; SMN2TSHRMGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969051-B2 | Process for producing optically active 2-alkyl-1,1,3-trialkoxycarbonylpropane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-03-03 | — | — | US | claimed |
| US-12617784-B2 | AKT inhibitor | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-3919491-B1 | AKT INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO LTD (CN) | 2025-05-28 | — | — | EP | disclosed |
| US-20230321108-A1 | UNIT DOSAGE COMPOSITION OF AKT INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230321108-A1 | UNIT DOSAGE COMPOSITION OF AKT INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230286979-A1 | SALT OF DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-09-14 | — | — | US | disclosed |
| US-20230286979-A1 | SALT OF DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-09-14 | — | — | US | disclosed |
| US-20230271958-A1 | SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271958-A1 | SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4186902-A1 | SALT OF DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| US-9309204-B2 | Process for making hydroxylated cyclopentylpyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309204-B2 | Process for making hydroxylated cyclopentylpyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150218602-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-ALKYL-1,1,3-TRIALKOXYCARBONYLPROPANE | GENENTECH INC (US) | 2015-08-06 | — | — | US | disclosed |
| EP-2861583-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | Array Biopharma, Inc. (US) | 2015-04-22 | — | — | EP | disclosed |
| US-20150099881-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | GENETECH, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099881-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | GENETECH, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-8969051-B2 | Process for producing optically active 2-alkyl-1,1,3-trialkoxycarbonylpropane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-03-03 | — | — | US | disclosed |
| WO-2013173736-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| US-20100240107-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-ALKYL-1,1,3-TRIALKOXYCARBONYLPROPANE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-2154253-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-ALKYL-1,1,3-TRIALKOXYCARBONYLPROPANE | Sumitomo Chemical Company, Limited (JP) | 2010-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099881-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | PIK3CA, DHPS, PIK3CD | SMN1; SMN2 3946/4885TSHR 3644/4885MGAM 4227/4885 |
| US-12617784-B2 | AKT inhibitor | AKT2, AKT1, AKT3 | SMN1; SMN2 1551/4885TSHR 900/4885MGAM 4031/4885 |
| US-20230321108-A1 | UNIT DOSAGE COMPOSITION OF AKT INHIBITOR | AKT2, AKT1, PIK3R2 | SMN1; SMN2 2468/4885TSHR 3863/4885MGAM 1820/4885 |
| US-20230286979-A1 | SALT OF DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | FH, GRHPR, SDHB | SMN1; SMN2 4120/4885TSHR 4842/4885MGAM 1406/4885 |
| US-20230271958-A1 | SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE | DCK, DPYD, UCK2 | SMN1; SMN2 3624/4885TSHR 3509/4885MGAM 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.